p38 mitogen-activated protein kinase is Required for glucosamine-induced endothelial nitric oxide synthase uncoupling and plasminogen- activator inhibitor expression

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 2015-2022

  Wu, Zongsong ^a   Xiong, Yuyan ^a   Gajanayake, Thusitha ^a,b   Ming, Xiu Fen ^a   Yang, Zhihong ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cardiovascular disease; Endothelial dysfunction; Nitric oxide; Oxidative stress; Risk factor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSAMINE; HEXOSAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; AORTA; CELLS, CULTURED; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GLUCOSAMINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864387130     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0016     Document Type: Article

References (51)

1. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
2. Heo KS, Fujiwara K, Abe J. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ J 2011; 75: 2722-2730.
3. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol 2011; 73: 503-514.
4. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Agedependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 491-496.
5. Hamsten A, Walldius G, Szamosi A, Blombäck M, Faire U, Dahlén G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 330: 3-9.
6. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
7. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
8. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883.
9. Förstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. Eur Heart J 2012; 33: 829-837.
10. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
11. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and niddm patients. Diabetes 1994; 43: 104-109.
12. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: Implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 2005; 66: 276-285.
13. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-1443.
14. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
15. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221.
16. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res 2010; 107: 171-185.
17. Einstein FH, Fishman S, Bauman J, Thompson RF, Huffman DM, Atzmon G, et al. Enhanced activation of a "nutrient-sensing" pathway with age contributes to insulin resistance. FASEB J 2008; 22: 3450-3457.
18. Srinivasan V, Tatu U, Mohan V, Balasubramanyam M. Molecular convergence of hexosamine biosynthetic pathway and ER stress leading to insulin resistance in L6 skeletal muscle cells. Mol Cell Biochem 2009; 328: 217-224.
19. Taylor RP, Parker GJ, Hazel MW, Soesanto Y, Fuller W, Yazzie MJ, et al. Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. J Biol Chem 2008; 283: 6050-6057.
20. Lima VV, Giachini FR, Carneiro FS, Carvalho MHC, Fortes ZB, Webb RC, et al. O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res 2011; 89: 614-622.
21. Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol 2007; 293: H1391-H1399.
22. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. J Biol Chem 2004; 279: 30133-30142.
23. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther 2012; 14: 201.
24. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-1348.
25. Musicki B, Kramer MF, Becker RE, Burnett AL. Inactivation of phosphorylated endothelial nitric oxide synthase (ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2005; 102: 11870-11875.
26. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-βI and -δ. J Biol Chem 2002; 277: 33833-33841.
27. -/- mice. Atherosclerosis 2011; 219: 134-140.
28. Tannock LR, Kirk EA, King VL, LeBoeuf R, Wight TN, Chait A. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. J Nutr 2006; 136: 2856-2861.
29. Werstuck GH, Khan MI, Femia G, Kim AJ, Tedesco V, Trigatti B, et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes 2006; 55: 93-101.
30. Cheung WD, Hart GW. AMP-activated protein kinase and p38 mapk activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol Chem 2008; 283: 13009-13020.
31. Goldberg H, Whiteside C, Fantus IG. O-linked β-N-acetylglucosamine supports p38 mapk activation by high glucose in glomerular mesangial cells. Am J Physiol Endocrinol Metab 2011; 301: E713-E726.
32. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-8477.
33. Rajapakse AG, Yepuri G, Carvas JM, Stein S, Matter CM, Scerri I, et al. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: Inhibition by resveratrol. PLoS One 2011; 6: e19237.
34. Volk T, Hensel M, Schuster H, Kox WJ. Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells. Mol Cell Biochem 2000; 206: 105-112.
35. Tabit C, Chung W, Hamburg N, Vita J. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74.
36. Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T. Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system. Review and perspective. Circ J 2011; 75: 1791-1800.
37. Nordt T, Klassen K, Schneider D, Sobel B. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb Vasc Biol 1993; 13: 1822-1828.
38. Rajapakse AG, Ming XF, Carvas JM, Yang Z. The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol 2009; 296: H815-H822.
39. Bhonagiri P, Pattar GR, Horvath EM, Habegger KM, McCarthy AM, Elmendorf JS. Hexosamine biosynthesis pathway flux contributes to insulin resistance via altering membrane phosphatidylinositol 4,5bisphosphate and cortical filamentous actin. Endocrinology 2009; 150: 1636-1645.
40. Rajamani U, Essop MF. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol 2010; 299: C139-C147.
41. Luo B, Soesanto Y, McClain DA. Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 651-657.
42. Rajapakse AG, Ming XF, Carvas JM, Yang Z. O-linked β-N-acetylglucosamine during hyperglycemia exerts both anti-inflammatory and pro-oxidative properties in the endothelial system. Oxid Med Cell Longev 2009; 2: 172-175.
43. Kaneto H, Xu G, Song KH, Suzuma K, Bonner-Weir S, Sharma A, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic β-cell function through the induction of oxidative stress. J Biol Chem 2001; 276: 31099-31104.
44. Singh LP, Cheng DW, Kowluru R, Levi E, Jiang Y. Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: Effect of the anti-oxidant α-lipoic acid. Cell Biochem Funct 2007; 25: 537-550.
45. Ying Y, Yang K, Liu Y, Chen QJ, Shen WF, Lu L, et al. A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ J 2011; 75: 2252-2259.
46. Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111: 1184-1191.
47. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SML, Mäki-Petäjä KM, et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2011; 123: 515-523.
48. Seeger F, Sedding D, Langheinrich A, Haendeler J, Zeiher A, Dimmeler S. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010; 105: 389-397.
49. Carlson CJ, Koterski S, Sciotti RJ, Poccard GB, Rondinone CM. Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes. Diabetes 2003; 52: 634-641.
50. Li SY, Liu Y, Sigmon VK, McCort A, Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-GlcNAc modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 2005; 7: 448-454.
51. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartilage 2007; 15: 764-772.